Biochemical and pharmacological evaluation of 2,4-difluorobenzyldimethylsilylmethanamine, a new highly selective inhibitor of monoamine oxidase-B.
Danzin
C
C
Marion Merrell Dow Research Institute, Strasbourg, France.
Zreika
M
M
Marchal
P
P
Petty
M
M
Collard
J N
JN
Schirlin
D
D
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000037:antagonists & inhibitors; D000284:Administration, Oral; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007700:Kinetics; D020267:MPTP Poisoning; D008297:Male; D008744:Methylamines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D017646:Organosilicon Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014439:Tyramine / Q000633:toxicity
C091486:2,4-difluorobenzyldimethylsilylmethanamine; D008744:Methylamines; D008996:Monoamine Oxidase Inhibitors; D017646:Organosilicon Compounds; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D014439:Tyramine